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Abstract
Background: Information about the risk factors associated with death caused by tuberculosis (TB)
or death with TB would allow improvements in the clinical care of TB patients and save lives. The
present study sought to identify characteristics associated with increased risk of death during anti-
TB treatment in Shanghai, a city in China with one of the country's highest TB mortality rates.
Methods: We evaluated deaths among culture positive pulmonary TB cases that were diagnosed
in Shanghai during 2000–2004 and initiated anti-TB therapy. Demographic, clinical,
mycobacteriological information and treatment outcomes were routinely collected through a
mandatory reporting system.
Results: There were 7,999 culture positive pulmonary cases reported during the study period.
The overall case fatality rate was 5.5% (440 cases), and approximately half (50.5%) of the deaths
were attributed to causes other than TB. Eighty-six percent of the deaths were among TB cases
age ≥ 60 years. The significant independent risk factors for mortality during anti-TB treatment were
advancing age, male sex, sputum smear positivity, and the presence of a comorbidity.
Conclusion: More vigorous clinical management and prevention strategies by both the TB control
program and other public health programs are essential to improve TB treatment outcomes.
Earlier suspicion, diagnosis and treatment of TB, especially among persons older than 60 years of
age and those with a comorbid condition, could reduce deaths among TB patients.
Background
Globally, tuberculosis (TB) caused 1.8 million deaths in
2007 [1], and TB is among the top ten causes of death
worldwide, especially in Asia and Africa [1,2]. Death is the
worst possible outcome for a person with TB. Information
about the determinants of death among TB patients could
help identify individuals who are at higher risk of death so
that targeted interventions can be implemented and TB
treatment outcomes can be improved. Risk factors such as
older age [3-5], a history of prior TB treatment [3,6],
multi-drug resistance (MDR) [3,6], HIV [4,7], comorbid-
ity [8], and incomplete treatment [9] are known to
increase the mortality associated with TB. However, the
risk factors for death among TB cases in China are
unknown.
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China reported the second-highest number of new TB
cases (1.31 million) and the second-highest number of TB
deaths (201,000 TB cases) in 2007, behind only India [1].
Shanghai is a metropolitan area located on the east coast
of China. Although the notification rate of pulmonary TB
in Shanghai (39.4/100 000 in 2000) [10] was lower than
the national rate (41.7/100 000 in 2000) [11], mortality
among TB patients in Shanghai (2.22/100 000 in 2000)
[10] was 56 times higher than the average national mor-
tality rate among TB patients (0.04/100 000 in 2000)
[11]. Of all of the notifiable communicable diseases in
Shanghai, TB ranked first in terms of reported deaths in
2000 [10]. In the present study, we sought to identify the
risk factors associated with death among pulmonary TB
patients during anti-TB treatment in Shanghai.
Methods
Study area
Shanghai is divided into 19 administrative regions. The
Shanghai Municipal Center for Disease Control and Pre-
vention (Shanghai CDC) manages the TB Control Pro-
gram for the municipality of Shanghai, and each of 19
regions in Shanghai has their own local government and
health activities, including the local TB control program.
There were approximately 16 million persons in Shanghai
in 2000, including 13.2 million local residents and an
estimated 3 million urban migrants (migrants from rural
areas in other provinces in China). The estimated popula-
tion density in Shanghai is over 2500 persons per square
kilometer.
TB surveillance
Beginning in the 1990s, a TB surveillance system and
mandatory reporting system for all pulmonary TB patients
were implemented in Shanghai. All suspected cases of pul-
monary TB at each hospital or clinic in Shanghai were
referred to a specialized TB hospital or TB clinic, where
demographic, clinical, and mycobacteriological informa-
tion, and the treatment outcome for each patient was col-
lected and reported to the TB Registry at Shanghai CDC.
While the treatment outcomes for Shanghai residents with
pulmonary TB patient were routinely reported to the TB
Registry, treatment outcomes for pulmonary TB patients
among urban migrants were not reported until 2005. As
culture remains the "gold standard" for TB diagnosis, and
is essential for traditional drug susceptiblity testing, we
used all culture-positive pulmonary TB patients among
local residents reported in Shanghai during 2000–2004 as
our study population.
Laboratory methods
Three sputum specimens were routinely collected from
each suspect TB case. Those individuals with bacteriologi-
cal confirmation of Mycobacterium tuberculosis (M. tubercu-
losis) in their smear and culture initiated anti-TB treatment
at a TB hospital or clinic. All of the pretreatment positive
cultures of M. tuberculosis in each laboratory were sent to
the Tuberculosis Reference Laboratory at Shanghai CDC
for drug susceptibility testing and specimen identifica-
tion. Drug susceptibility testing was routinely performed
on isolates of M. tuberculosis for isoniazid, rifampin,
ethambutol and streptomycin on Lowenstein-Jensen (LJ)
solid medium [12].
Treatment
In general, new pulmonary TB patients received two
months of treatment with isoniazid (H), rifampin (R),
pyrazinamide (Z), and ethambutol (E) (or streptomycin
(S)) during the intensive phase and four months of isoni-
azid and rifampin during the continuation phase
(2HRZE(S)/4HR). Retreatment pulmonary TB patients
received treatment using 2HRZES/1HRZE/5HRE or
2HRZES/6HRE. Both the intensive phase and the contin-
uation phase of anti-TB therapy could be extended,
depending on radiological and bacteriological data that
were available and the clinical judgment of the treating
physician.
Definitions
A suspected case of pulmonary TB was defined as an indi-
vidual with an unexplained productive cough during the
previous 2–3 weeks. A TB case was defined as an individ-
ual who was sputum smear positive or culture positive for
M. tuberculosis. A new TB case was defined as a TB case
without a previous history of TB treatment. A retreatment
TB case was defined as a TB case who had previously
received at least 30 days of anti-TB treatment any time
during their life. MDR was defined as resistance to at least
isoniazid and rifampin. Treatment success and transfer
out of the district were defined according to international
definitions [13]. The cause of death was determined based
on the information from the death certificate. A TB death
was defined as a TB case whose treatment outcome was
recorded as death caused by TB, or death with TB as a con-
tributing cause. All remaining deaths were defined as non-
TB deaths.
In the present study, TB cases were followed from the time
they initiated treatment until they stopped treatment for
any reason, such as a death, default, transfer, move, or suc-
cessful completion of therapy. However, we excluded
from the analysis those TB cases whose treatment
extended beyond 12 months, those who moved or trans-
ferred out of Shanghai, and those for whom no informa-
tion was available about the treatment outcome.
Treatment outcomes for pulmonary TB patients among
urban migrants were not reported until 2005 and they
were also excluded from the analysis. Comorbidity was
defined as a chronic illness, such as diabetes, cardiovascu-
lar disease, cancer, or chronic obstructive pulmonary dis-BMC Infectious Diseases 2009, 9:95 http://www.biomedcentral.com/1471-2334/9/95
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ease, or a concurrent infectious disease such as hepatitis or
pneumonia. In this study, comorbidity was recorded as
the presence or absence of a comorbidity, but precise
information was not collected about the actual disease
condition.
Statistical analysis
We used univariate and multivariate analyses to deter-
mine the characteristics of the TB cases that were associ-
ated with an increased risk of all cause mortality during
anti-TB treatment. The independent variables studied
included demographic characteristics (i.e., age, sex), clini-
cal characteristics (i.e., previous TB history, cavity on ini-
tial chest radiograph, comorbidity), and sputum smear
status. All independent variables were examined as cate-
gorical variables. Odd ratios (ORs) and 95% confidence
intervals (CI) were calculated to measure the association
between TB patient characteristics and death, at the uni-
variate and multivariate level. All variables with a p value
< 0.20 in the univariate analysis were considered for the
multivariate logistic regression model. Forward stepwise
model construction was performed and the log likelihood
ratios of successive models were compared until the final,
most parsimonious model was identified. We tested for
interaction between those variables with a p value < 0.05
in the multivariate model, and kept the interaction terms
in the multivariate model if they were significant (p  <
0.05). All analyses used Stata statistical software (version
8.0SE, Stata Corporation, College Station, Texas, USA).
Ethical approval
The study was approved by the Committee for Medical
Research Ethics at Shanghai CDC and the University of
California, Davis.
Results
There were a total of 21,292 pulmonary TB cases reported
in Shanghai during 2000–2004. Of these, 15,035 (70.6%)
had a sputum culture result available and 8,018 of the TB
cases were sputum culture positive. TB cases who were
male (72.0% versus 67.2%; p < 0.001), had cavity on ini-
tial chest radiograph (74.3% versus 70.0%; p < 0.001),
and had a comorbidity (72.9% versus 70.3%, p = 0.002)
were more likely to have sputum culture results available.
We also tested the proportion of other subgroups (by age
group, sputum smear status, new cases versus retreatment
cases), but no significant differences were observed
between TB cases who did and did not have a culture
result.
Of the 8,018 culture-positive pulmonary TB cases, 7,999
cases initiated anti-TB treatment (Figure 1). Of the 7,999
cases initiated anti-TB treatment, 16.9% were followed for
up to 6 months, 49.2% were followed for up to 9 months,
and 33.9% were followed for up to 12 months. The
median follow up period was 229 days for all cases, 219
days for new cases, and 272 days for retreatment cases (p
< 0.001). At the end of one year follow-up, a total of 7,433
(92.9%) treated cases were alive (6,595 were considered a
treatment success, and 838 were continuing treatment),
and 440 (5.5%) cases had died prior to completion of
therapy. One hundred and twenty-six cases had either
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transferred out of Shanghai or their treatment status was
unknown, and they were excluded in the analysis. Among
the TB cases who died, 49.5% (218/440) of the deaths
were directly caused by TB, and 50.5% (222/440) were
caused by a cause other than TB. Among new TB cases,
49.8% of all deaths were attributable to causes other than
TB, while among retreatment TB cases, 46.7% of all deaths
were attributable to causes other than TB (p = 0.441). In
addition, 85.7% of the deaths were among TB cases age ≥
60 years (Table 1).
The characteristics of the study population are presented
in Table 1. The median age of all TB cases in the study was
52 years. TB cases were predominantly male (77.9%).
Most TB cases were new cases (81.1%). Thirty percent of
all of the TB cases had a cavity on their initial chest radio-
graph and 80.4% were sputum smear positive. Twenty
percent of all TB cases had a comorbid condition, and
3.2% of the TB cases had MDR.
Risk factors for on-treatment mortality
Based on the univariate analysis, the characteristics of the
TB patients associated with mortality during anti-TB treat-
ment were age 30–44 years, age 45–59 years, age 60–74
years, age ≥ 75 years, male sex, being a retreatment case,
the presence of a cavity on the initial chest radiograph,
sputum smear positivity, and the presence of a comorbid-
ity (Table 2). In the final multivariable logistic regression
model (Table 2), TB cases with age 30–44 years (adjusted
OR = 5.0, 95% CI: 1.2–21.7), age 45–59 years (adjusted
OR = 8.2, 95% CI: 2.0–34.3), age 60–74 years (adjusted
OR = 35.4, 95% CI: 8.7–143.6), age ≥ 75 years (adjusted
OR = 82.3, 95% CI: 20.3–333.2), males (adjusted OR =
1.7, 95% CI: 1.2–2.3), those with a postive sputum smear
result (adjusted OR = 1.6, 95% CI: 1.2–2.2), and those
who had a comorbidity (adjusted OR = 1.4, 95% CI: 1.1–
1.7) were more likely to die during anti-TB treatment.
None of the interaction terms were significant in the mul-
tivariable logistic regression model, and were removed.
Table 1: Characteristics of the 7,873 study participants with tuberculosis (TB), Shanghai, 2000–2004
Characteristics Total Survived Died
No. (%) No. (%) No. (%)
Age (years)
Median (range, years) 52 (11–100) 51 (11–100) 74 (19–92)
11–14 33 (0.4) 33 (0.4) 0 (0.0)
15–29 1003 (12.7) 1001 (13.5) 2 (0.5)
30–44 1643 (20.9) 1624 (21.8) 19 (4.3)
45–59 1966 (25.0) 1924 (25.9) 42 (9.5)
60–74 2057 (26.1) 1883 (25.3) 174 (39.5)
≥ 75 1171 (14.9) 968 (13.0) 203 (46.1)
Sex
Female 1736 (22.1) 1681 (22.6) 55 (12.5)
Male 6137 (77.9) 5752 (77.4) 385 (87.5)
Case type
New case 6383 (81.1) 6056 (81.5) 327 (74.3)
Retreatment case 1490 (18.9) 1377 (18.5) 113 (25.7)
Cavity on initial chest radiograph
Absent 5258 (66.8) 4943 (66.5) 315 (71.6)
Present 2376 (30.2) 2266 (30.5) 110 (25.0)
Uncertain 239 (3.0) 224 (3.0) 15 (3.4)
Sputum smear
Negative 1461 (18.6) 1416 (19.0) 45 (10.2)
Positive 6334 (80.4) 5945 (80.0) 389 (88.4)
Unkown 78 (1.0) 72 (1.0) 6 (1.4)
Comorbidity
Absent 6231 (79.1) 5938 (79.9) 293 (66.6)
Present 1608 (20.4) 1466 (19.7) 142 (32.3)
Unknown 34 (0.4) 29 (0.4) 5 (1.1)
Drug susceptibility results
Non-MDR 4714 (59.9) 4487 (60.4) 227 (51.6)
MDR 256 (3.2) 241 (3.2) 15 (3.4)
Unknown 2903 (36.9) 2705 (36.4) 198 (45.0)
TB = tuberculosis; MDR = multidrug resistanceBMC Infectious Diseases 2009, 9:95 http://www.biomedcentral.com/1471-2334/9/95
Page 5 of 7
(page number not for citation purposes)
A high proportion of TB cases (36.9%) had missing data
on MDR status. We developed a multivariable logistic
regression model that was restricted to TB cases whose
drug susceptibility test results were available. Characteris-
tics of the TB patients that were significantly associated
with on-treatment mortality were same as the model that
included all culture-positive TB patients. We concluded
that MDR was not significantly associated with on-treat-
ment mortality in our study population (OR = 1.3, 95%
CI: 0.7–2.3).
Discussion
The case fatality rate among TB cases in Shanghai during
2000 to 2004 was 5.5%. The significant independent risk
factors for on-treatment mortality among TB cases were
advancing age, male sex, sputum smear positivity, and the
presence of a comorbidity. These results suggest that more
vigorous efforts should be made by both TB control pro-
grams and other public health programs to improve TB
treatment outcomes and to reduce the mortality among
TB patients.
Our analysis showed that approximately half (49.5%) of
the deaths were cause by TB or TB was a contributing case,
and the remainder 50.5%) were due to one or more causes
other than TB. In previous studies, the proportion of
deaths due to a cause other than TB was 98.6% in the
United States of American and Canada [4], 86% in the
Netherlands [7], 43% in England and Wales [14], 27.3%
in Mexico [15], and 24.6% in Russia [3]. Interestingly, the
proportions of deaths due to causes other than TB in
developed countries were higher in industrialized coun-
tries than in developing countries, but there were also
fewer studies conducted in developing countries. Perhaps
in settings with a relatively low incidence of TB, deaths
among TB patients were more likely to be attributed to an
underlying medical conditions (e.g., older age, illness
with a comorbidity, HIV, alcohol use), but not TB. In con-
trast, in high-incidence settings, TB was more common
among younger individuals and ongoing transmission of
M. tuberculosis was likely to occur. The high proportion
(50.5%) of deaths among TB cases in Shanghai that were
due to causes other than TB suggests that TB cases may
require more intensive medical evaluation and care than
is usually provided by traditional TB control programs.
Table 2: Results of the univariate and multivariate analysis of the characteristics of tuberculosis (TB) patients associated with death 
during anti-TB treatment, Shanghai, 2000–2004
Characteristics Survived Died OR (95% CI) P value AOR (95% CI) P value
No. (%) No. (%)
Age (years)
11–29 1034 (13.9) 2 (0.5) 1.0 1.0
30–44 1624 (21.8) 19 (4.3) 6.0 (1.5–53.6) 0.006 5.0 (1.2–21.7) 0.031
45–59 1924 (25.9) 42 (9.5) 11.3 (2.9–96.4) <0.001 8.2 (2.0–34.3) 0.004
60–74 1883 (25.3) 174 (39.5) 47.8 (13.0–398.1) <0.001 35.4 (8.7–143.6) <0.001
≥ 75 968 (13.0) 203 (46.1) 108.4 (29.5–902.7) <0.001 82.3 (20.3–333.2) <0.001
Sex
Female 1681 22.6 55 12.5 1.0 1.0
Male 5752 77.4 385 87.5 2.0 (1.5–2.8) <0.001 1.7 (1.2–2.3) 0.001
Case type
New case 6056 81.5 327 74.3 1.0 -
Retreatment case 1377 18.5 113 25.7 1.5 (1.2–1.9) <0.001 -
Cavity on initial chest radiograph
Absent 4943 66.5 315 71.6 1.0 -
Present 2266 30.5 110 25.0 0.8 (0.6–0.9) 0.016 -
Uncertain 224 3.0 15 3.4 - -
Sputum Smear
Negative 1461 18.6 1416 19.0 1.0 1.0
Positive 6334 80.4 5945 80.0 2.1 (1.5–2.9) <0.001 1.6 (1.2–2.2) 0.004
Unknown 78 1.0 72 1.0 - -
Comorbidity
Absent 5938 79.9 293 66.6 1.0 1.0
Present 1466 19.7 142 32.3 2.0 (1.6–2.4) <0.001 1.4 (1.1–1.7) 0.004
Unknown 29 0.4 5 1.1 - -
Drug susceptibility results
Non-MDR 4487 60.4 227 51.6 1.0 -
MDR 241 3.2 15 3.4 1.2 (0.7–2.1) 0.450 -
Unknown 2705 36.4 198 45.0 1.4 (1.2–1.8) <0.001 -
TB = tuberculosis; OR = odds ratio; AOR = adjusted odds ratio; CI = confidence interval; MDR = multidrug resistanceBMC Infectious Diseases 2009, 9:95 http://www.biomedcentral.com/1471-2334/9/95
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The finding also suggests that TB control programs should
interact with other public health programs, since such
deaths may not be preventable by improvements in the TB
services alone.
In our study, advancing age was strongly associated with
on-treatment mortality and is a likely confounder of the
association of male sex, sputum smear status and comor-
bidities with on-treatment mortality. Given the increasing
numbers of elderly persons in Shanghai (11.5% of the
entire population was aged ≥ 65 years in 2000), TB mor-
tality among the elderly has been an enormous concern.
The aging population in Shanghai could be one of the rea-
sons why the case fatality rate of TB cases was high. Gen-
erally, older patients experience unfavorable living
conditions, malnutrition, comorbidities and less access to
health care, any of which could increase the risk of death.
It is possible that older TB cases had a high mortality rate
because they were more likely to present with nonspecific
symptoms, which may contribute to delays in diagnosis
and treatment of TB and, ultimately, a higher risk of death
[16,17]. More vigorous clinical management and preven-
tion strategies including earlier suspicion, diagnosis and
treatment of TB may reduce deaths among older patients.
In addition, elderly people may present with more exten-
sive TB disease, based on the initial chest radiograph
[16,18].
Male sex was significantly associated with mortality in our
study as well as in some previously studies [6,7,19]. A
recent analysis of European surveillance data showed that
male TB patients had approximately 50% higher risk of
death [6]. However, other studies failed to detect a signif-
icant association between male gender and death among
TB patients [4,5,20]. The higher risk in male patients was
explained by some authors as the consequence of low
compliance with anti-TB therapy, leading to repeated,
short interruptions of treatment, or a greater occurrence of
defaulting from treatment. Better case-holding strategies,
such as directly observed therapy (DOT), may improve
treatment outcomes [6,21].
The association between sputum smear positivity and on-
treatment mortality was notable in our study. To our
knowledge, this finding has not been previously reported.
We speculate that patients who were sputum smear posi-
tive had a higher bacillary load, suffered from more severe
TB, and had difficulty with their treatment. Further evi-
dence is needed to support this speculation.
Comorbidity was previously reported as an important
predictor of on-treatment mortality among TB patients
[5,8,20]. The most common diseases that were listed with
TB as the cause of death included HIV/AIDS, renal dis-
eases, liver disease, cardiovascular disease, cancer, chronic
obstructive pulmonary disease (COPD), and diabetes
[3,4,7,8,20,22]. However, the effect of underlying diseases
other than HIV/AIDS on the risk of death due to TB has
not been studied extensively. Some diseases, such as renal
disease and liver disease, may change the presentation of
TB, making it more difficult to diagnose and treat and they
may be associated with increased risk of toxicity caused by
anti-TB drugs [23]. In our study, comorbidities were sig-
nificantly associated with death among TB cases.
Although we did not know the actual disease that caused
death, TB screening among patients with other conditions
which increase the risk of deaths might be helpful to
detect TB early and to improve TB treatment outcomes.
Our study had several limitations. First, we determined
the cause of death using death certificate data. In other set-
tings, death certificates were at least partially unreliable
[24]. However, in Shanghai, a death registration system
was established during the 1990s based on the World
Health Organization's International Classification of Dis-
ease (ICD) to classify the causes of death. Although the TB
registry was separate from the death registration system in
Shanghai, the death reports of these two systems are con-
ducted by same local institutes. While it is possible that
some misclassification of TB deaths or non-TB deaths
occurred, the misclassification bias should have been
minimized by the death registration system. Second, the
proportion (36.9%) of missing data on MDR status,
which was a strong predictor of death in other studies
[3,6], was high in our study, and the prevalence of MDR
might have been underestimated. However, in a multivar-
iate logistic regression model based on those pulmonary
TB patients who had a drug susceptibility test result avail-
able, MDR was not significantly associated with death
during anti-TB treatment. Third, we excluded the TB cases
among urban migrants from our analysis, as their treat-
ment outcomes were not reported during the study
period. However, migrant TB patients in Shanghai were
commonly young, and deaths among them occurred
infrequently (in 2006, only 8 cases were known to have
died from TB). We assumed that most of the burden of TB
deaths in Shanghai were among the local residents.
Finally, HIV status, which was strongly associated with
death among TB patients in other studies, was not availa-
ble in our study. However, another ongoing study in
Shanghai determined that the prevalence of HIV among
TB patients is very low (<0.1%). We assumed that HIV
infection was not significantly associated with death
among TB patients in Shanghai.
Conclusion
A substantial number of deaths occurred among pulmo-
nary TB patients during anti-TB treatment in Shanghai,
but a high proportion of deaths among pulmonary TB
cases in Shanghai were attributable to causes other thanBMC Infectious Diseases 2009, 9:95 http://www.biomedcentral.com/1471-2334/9/95
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TB. Both TB control programs and other public health
programs should be strengthened and should interact
with each other to improve the TB treatment outcomes
and to prevent unnecessary deaths. Patients with advanc-
ing age, male sex, sputum smear positivity, and a comor-
bidity have the highest risk of death during anti-TB
treatment. Our findings highlight the importance of
improved clinical management and prevention strategies
that target TB patients at increased risk of death. Further
studies are needed to identify and evaluate interventions
that reduce mortality among TB patients.
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